miReven scientists awarded an Australian competitive NHMRC Development grant for 2022-23
New Award – miReven scientists awarded an Australian competitive NHMRC Development grant for 2022-23. Prof Leedman and the team were successful in being awarded a Development Grant for two years to help drive the further development of mRx-7 into a therapy for liver cancer.
mRx-7 presented at the American Association for Cancer Research
At a virtual conference hosted by the American Association for Cancer Research (AACR), April 10-15 2021, preliminary results of mRx-7 were presented by Prof Peter Leedman. The AACR Annual Meeting program covers the latest discoveries across the spectrum of cancer research—from population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and […]
mRx-7 and microRNAs in cancer presented to the National Gene Therapy meeting in Brisbane
National Gene Therapy Meeting Recent findings for the progression of mRx-7 were presented at the Annual Joint Scientific Meeting hosted by the Australian Society for Stem Cell Research (ASSCR), Australasian Gene and Cell Therapy Society (AGCTS), and the International Society for Cell & Gene Therapy (ISCT) in Brisbane, Queensland, Australia. This conference, which spanned November […]
mRx-7 and microRNAs in cancer presented to Sun Yat-Sen University Hospital, China
In July of 2019, Prof Peter Leedman visited Sun Yat-Sen University Hospital, Guangzhou, Guangdong, China to present the latest findings for the progression of mRx-7 as a new anti-cancer therapeutic.
Prof Peter Leedman presents recent results at FNA meeting
Prof Peter Leedman presented the latest promising results of mRx-7 at the Functional Nucleic Acid (FNA) Meeting, held at Murdoch University in Perth, Western Australia on November 22. The meeting featured international, interstate and local invited speakers to present their research on the recent advances in essentially redesigning the building blocks of life for diagnostic […]
miReven scientists evaluate microRNA-7 delivery
miReven scientists evaluate microRNA-7 delivery in preclinical models and methods for quantitation and publish in Methods of Molecular Biology 2018
miReven scientists publish in Hepatology
miReven scientists publish paper in prestigious journal Hepatology identifying new pathways that mediate resistance to sorafenib and showing that microRNA-7 can overcome therapeutic resistance in liver cancer 10 January 2018 Hepatology 2018
miReven scientists publish in Oncotarget
miReven scientists show that microRNA-7 inhibits melanoma cell proliferation and metastasis and publish in Oncotarget 31 May 2016
miReven Scientists Awarded $530k Grant to Advance miR-7 Cancer Therapeutic
miReven scientists have been awarded a $530,000 NHMRC Development Grant to advance miR-7 as a novel cancer therapeutic. Chief Investigators on the project Prof. Peter Leedman and Dr Christopher Wraight will apply the funding to the development of a series of novel miR-7 mimics with optimised drug-like properties. The project builds on the successful preclinical […]
microRNA-7: A tumor suppressor miRNA with therapeutic potential
MiReven scientists have published a review on Micro RNA-7 in the June 2014 edition of The International Journal of Biochemistry & Cell Biology. The article, entitled “microRNA-7: A tumor suppressor miRNA with therapeutic potential“, is part of a Directed Issue of the Journal entitled, “The Non-coding RNA Revolution”. The co-authors of the article feature miReven scientific founders Felicity […]